Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (768)	9/18/2000 2:09:52 PM
From: JDN	Read Replies (1) \| Respond to of 783

Dear Paul Senior: I think the key to whether or not BCHE will be an outstanding investment is whether or not they will be able to successfully produce and market their next line of drugs themselves. Previously they have had GLAXO marketing and distributing their most successful drug. This has given them considerable cash etc. and decent earnings (especially for the price of the stock) but not a lot of UPSIDE opportunity. At these prices I think its worth dipping your feet in to test the waters. JDN

To: Paul Senior who wrote (768)	9/18/2000 9:19:45 PM
From: Aggie	Respond to of 783

Paul Senior, good evening. I'm considering establishing a small position. The smaller the better, try zero shares as a good start. I've owned this dog for a number of years, and managed to dump half my considerable position at a very slim profit - not even enough to cover the extra Digel. As far as I'm concerned, this is one management boondoggle scheme after another, and I'm pretty well disgusted with this POS stock's consistent performance of not living up to any performance targets at all. Buyer beware. Regards to all, Aggie